Chengdu New Radiomedicine Technology Co., Ltd. (“NRT”), founded in 2016 by veterans in nuclear technology, focuses on radiopharmaceuticals and medical isotopes development, with integrated capabilities across the value chain, from R&D, production to commercialization. 

NRT has multiple branches in China and global presence in the United States and Australia. Our cross-disciplinary team work together to accelerate the advancement of radioligand therapy (RLT), innovation of radioactive microspheres and development of medical isotopes. The company has completed installation of a commercial 30MeV cyclotron and is ready for production of important therapeutic and diagnostic isotopes. 

NRT is committed to becoming a leading enterprise in the field of innovative radiopharmaceutical development.